Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Gut

Retrieve available abstracts of 105 articles:
HTML format

Single Articles

    December 2022
  1. ADOLPH TE, Zhang J
    Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts.
    Gut. 2022;71:2574-2586.
    PubMed     Abstract available

  2. SALAS A
    What good can neutrophils do in UC?
    Gut. 2022;71:2375-2376.

  3. LETT MJ, Mehta H, Keogh A, Jaeger T, et al
    Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells.
    Gut. 2022;71:2526-2538.
    PubMed     Abstract available

    November 2022
  4. MANSOOR E, Martin SA, Perez A, Nguyen VQ, et al
    Reply to Newman et al 'Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
    Gut. 2022 Nov 2. pii: gutjnl-2022-328883. doi: 10.1136/gutjnl-2022-328883.

  5. SCHIEPATTI A, Sanders DS, Baiardi P, Caio G, et al
    Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus.
    Gut. 2022;71:2218-2225.
    PubMed     Abstract available

  6. ROSATI E, Rios Martini G, Pogorelyy MV, Minervina AA, et al
    A novel unconventional T cell population enriched in Crohn's disease.
    Gut. 2022;71:2194-2204.
    PubMed     Abstract available

  7. HUO X, Li D, Wu F, Li S, et al
    Cultivated human intestinal fungus Candida metapsilosis M2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists.
    Gut. 2022;71:2205-2217.
    PubMed     Abstract available

  8. WARD D, Andersson M, Nyboe Andersen N, Allin KH, et al
    Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study.
    Gut. 2022;71:2373-2374.

    October 2022
  9. NEWMAN KL, Jencks K, Chedid V, Paul S, et al
    Response to Mansoor et al: 'epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
    Gut. 2022 Oct 13. pii: gutjnl-2022-328802. doi: 10.1136/gutjnl-2022-328802.

    September 2022
  10. SUDHAKAR P, Wellens J, Verstockt B, Ferrante M, et al
    Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
    Gut. 2022 Sep 28. pii: gutjnl-2022-328221. doi: 10.1136/gutjnl-2022-328221.
    PubMed     Abstract available

  11. ZOLLER H, Wolf M, Blumenstein I, Primas C, et al
    Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Gut. 2022 Sep 9. pii: gutjnl-2022-327897. doi: 10.1136/gutjnl-2022-327897.
    PubMed     Abstract available

  12. KIRCHGESNER J, Desai RJ, Schneeweiss MC, Beaugerie L, et al
    Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
    Gut. 2022;71:1781-1789.
    PubMed     Abstract available

  13. CANNATELLI R, Ferretti F, Carmagnola S, Bergna IMB, et al
    Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD.
    Gut. 2022;71:1926-1928.

  14. FAIRBRASS KM, Lovatt J, Barberio B, Yuan Y, et al
    Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis.
    Gut. 2022;71:1773-1780.
    PubMed     Abstract available

  15. MANSOOR E, Martin SA, Perez A, Nguyen VQ, et al
    Epidemiology of inflammatory bowel disease in men with high-risk homosexual activity.
    Gut. 2022 Sep 1. pii: gutjnl-2022-328218. doi: 10.1136/gutjnl-2022-328218.

    August 2022
  16. KEDIA S, Virmani S, K Vuyyuru S, Kumar P, et al
    Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial.
    Gut. 2022 Aug 16. pii: gutjnl-2022-327811. doi: 10.1136/gutjnl-2022-327811.
    PubMed     Abstract available

  17. RIMOLA J, Torres J, Kumar S, Taylor SA, et al
    Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease.
    Gut. 2022 Aug 4. pii: gutjnl-2021-326562. doi: 10.1136/gutjnl-2021-326562.
    PubMed     Abstract available

  18. GUO X, Chong L, Zhang X, Li R, et al
    Letter to the editor: Genetically determined IBD is associated with decreased risk of Alzheimer's disease: a Mendelian randomisation study.
    Gut. 2022;71:1688-1689.

  19. ADOLPH TE, Siegmund B
    Deciphering the vedolizumab dosing conundrum in IBD: when less is more.
    Gut. 2022;71:1455-1456.

  20. BECKER E, Dedden M, Gall C, Wiendl M, et al
    Residual homing of alpha4beta7-expressing beta1(+)PI16(+) regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.
    Gut. 2022;71:1551-1566.
    PubMed     Abstract available

    July 2022
  21. IACUCCI M, Parigi TL, Bazarova A, Ghosh S, et al
    Response to: Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificia
    Gut. 2022 Jul 27. pii: gutjnl-2022-327980. doi: 10.1136/gutjnl-2022-327980.

  22. XIONG S, Whitehurst CE, Li L, Heo GS, et al
    Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response.
    Gut. 2022;71:1289-1301.
    PubMed     Abstract available

    June 2022
  23. DANESE S, Solitano V, Jairath V, Peyrin-Biroulet L, et al
    The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment).
    Gut. 2022 Jun 14. pii: gutjnl-2022-327025. doi: 10.1136/gutjnl-2022-327025.

  24. WONG ECL, Dulai PS, Narula N
    Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligenc
    Gut. 2022 Jun 7. pii: gutjnl-2022-327661. doi: 10.1136/gutjnl-2022-327661.

  25. STIDHAM RW, Vickers A, Singh K, Waljee AK, et al
    From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD?
    Gut. 2022;71:1046-1047.

  26. KAPLAN GG, Ma C, Charlton C, Kanji JN, et al
    Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.
    Gut. 2022;71:1229-1231.

  27. NARULA N, Wong ECL, Colombel JF, Sandborn WJ, et al
    Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).
    Gut. 2022;71:1078-1087.
    PubMed     Abstract available

    May 2022
  28. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.
    Gut. 2022 May 23. pii: gutjnl-2022-327440. doi: 10.1136/gutjnl-2022-327440.

    April 2022
  29. LIN S, Lau LH, Chanchlani N, Kennedy NA, et al
    Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Gut. 2022 Apr 27. pii: gutjnl-2021-326784. doi: 10.1136/gutjnl-2021-326784.
    PubMed     Abstract available

  30. VOSKENS C, Stoica D, Rosenberg M, Vitali F, et al
    Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.
    Gut. 2022 Apr 15. pii: gutjnl-2022-327075. doi: 10.1136/gutjnl-2022-327075.
    PubMed     Abstract available

  31. JESS T, Vestergaard MV, Iversen AT, Allin KH, et al
    Undiagnosed inflammatory bowel disease among individuals undergoing colorectal cancer screening: a nationwide Danish cohort study 2014-2018.
    Gut. 2022 Apr 12. pii: gutjnl-2022-327296. doi: 10.1136/gutjnl-2022-327296.

  32. RAINE T, Pavey H, Qian W, Moran GW, et al
    Establishment of a validated central reading system for ileocolonoscopy in an academic setting.
    Gut. 2022;71:661-664.

  33. JIMENEZ-VARGAS NN, Yu Y, Jensen DD, Bok DD, et al
    Agonist that activates the micro-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.
    Gut. 2022;71:695-704.
    PubMed     Abstract available

    March 2022
  34. GORDON IO, Bettenworth D, Bokemeyer A, Srivastava A, et al
    International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease.
    Gut. 2022;71:479-486.
    PubMed     Abstract available

  35. PAGANO E, Elias JE, Schneditz G, Saveljeva S, et al
    Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment.
    Gut. 2022;71:509-520.
    PubMed     Abstract available

    February 2022
  36. GUI X, Bazarova A, Del Amor R, Vieth M, et al
    PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326376. doi: 10.1136/gutjnl-2021-326376.
    PubMed     Abstract available

  37. LI X, Tong X, Wong ICK, Peng K, et al
    Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study.
    Gut. 2022 Feb 8. pii: gutjnl-2021-326860. doi: 10.1136/gutjnl-2021-326860.

  38. MA C, Khanna R, Guizzetti L, Zou G, et al
    Methods for handling missing segments in Crohn's disease clinical trials: analysis from the EXTEND trial.
    Gut. 2022;71:447-448.

  39. LIU Z, Liu X, Liang J, Shi Y, et al
    Unusual cause of bloody stool with earache and saddle-nose deformity.
    Gut. 2022;71:264-356.

    January 2022
  40. SPALINGER MR, Shawki A, Chatterjee P, Canale V, et al
    Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence.
    Gut. 2022;71:89-99.
    PubMed     Abstract available

  41. MAO R, Doyon G, Gordon IO, Li J, et al
    Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease.
    Gut. 2022;71:55-67.
    PubMed     Abstract available

  42. JONGSMA MME, Aardoom MA, Cozijnsen MA, van Pieterson M, et al
    First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Gut. 2022;71:34-42.
    PubMed     Abstract available

    December 2021
  43. BURR NE, Gracie DJ, Black CJ, Ford AC, et al
    Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.
    Gut. 2021 Dec 22. pii: gutjnl-2021-326390. doi: 10.1136/gutjnl-2021-326390.
    PubMed     Abstract available

  44. WELLENS J, Edmans M, Obolski U, McGregor CG, et al
    Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
    Gut. 2021 Dec 15. pii: gutjnl-2021-326312. doi: 10.1136/gutjnl-2021-326312.

  45. LEPPKES M, Lindemann A, Gosswein S, Paulus S, et al
    Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis.
    Gut. 2021 Dec 3. pii: gutjnl-2021-324725. doi: 10.1136/gutjnl-2021-324725.
    PubMed     Abstract available

  46. MCGREGOR CG, Adams A, Sadler R, Arancibia-Carcamo CV, et al
    Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
    Gut. 2021;70:2398-2400.

  47. WELLENS J, Sabino J, Vermeire S
    PPIs and anti-TNF in patients with IBD: a forbidden combination?
    Gut. 2021;70:2397-2398.

  48. NA YR, Jung D, Stakenborg M, Jang H, et al
    Prostaglandin E2 receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation.
    Gut. 2021;70:2249-2260.
    PubMed     Abstract available

    November 2021
  49. SHIRE ZJ, Reicherz F, Lawrence S, Sudan H, et al
    Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy.
    Gut. 2021 Nov 23. pii: gutjnl-2021-326196. doi: 10.1136/gutjnl-2021-326196.

  50. CROUWEL F, Buiter HJC, de Boer NKH
    There is still a place for optimised thiopurine therapy in IBD.
    Gut. 2021;70:2207.

    October 2021
  51. ODUFALU FD, Long M, Lin K, Mahadevan U, et al
    Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry.
    Gut. 2021 Oct 22. pii: gutjnl-2021-325317. doi: 10.1136/gutjnl-2021-325317.
    PubMed     Abstract available

  52. ATTAUABI M, Seidelin J, Burisch J
    Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?
    Gut. 2021;70:2020-2022.

  53. KENNEDY NA, Lin S, Goodhand JR, Chanchlani N, et al
    Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Gut. 2021;70:1884-1893.
    PubMed     Abstract available

  54. JUKIC A, Bakiri L, Wagner EF, Tilg H, et al
    Calprotectin: from biomarker to biological function.
    Gut. 2021;70:1978-1988.
    PubMed     Abstract available

    September 2021
  55. KHAN N, Mahmud N, Trivedi C, Reinisch W, et al
    Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
    Gut. 2021;70:1657-1664.
    PubMed     Abstract available

  56. ADEGBOLA SO, Dibley L, Sahnan K, Wade T, et al
    Development and initial psychometric validation of a patient-reported outcome measure for Crohn's perianal fistula: the Crohn's Anal Fistula Quality of Life (CAF-QoL) scale.
    Gut. 2021;70:1649-1656.
    PubMed     Abstract available

  57. KANDIAH K, Subramaniam S, Thayalasekaran S, Chedgy FJ, et al
    Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial).
    Gut. 2021;70:1684-1690.
    PubMed     Abstract available

    August 2021
  58. GORELIK Y, Freilich S, Gerassy-Vainberg S, Pressman S, et al
    Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFalpha therapy in inflammatory bowel disease patients: a report from the epi-IIRN.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325185. doi: 10.1136/gutjnl-2021-325185.
    PubMed     Abstract available

    July 2021
  59. VERSTOCKT B, Boets L, Sabino J, Vermeire S, et al
    Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease.
    Gut. 2021;70:1416-1418.

  60. CARON B, Sandborn WJ, Schreiber S, Panaccione R, et al
    Drug development for ulcerative proctitis: current concepts.
    Gut. 2021;70:1203-1209.

    June 2021
  61. HANSEN R, Meade S, Beattie RM, Auth MK, et al
    Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Gut. 2021;70:1044-1052.
    PubMed     Abstract available

  62. AGRAWAL M, Corn G, Shrestha S, Nielsen NM, et al
    Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study.
    Gut. 2021;70:1037-1043.
    PubMed     Abstract available

    May 2021
  63. CURTIUS K, Kabir M, Al Bakir I, Choi CHR, et al
    Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool.
    Gut. 2021 May 14. pii: gutjnl-2020-323546. doi: 10.1136/gutjnl-2020-323546.
    PubMed     Abstract available

  64. KENNEDY NA, Goodhand JR, Bewshea C, Nice R, et al
    Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
    Gut. 2021;70:865-875.
    PubMed     Abstract available

  65. AXELRAD JE, Olen O, Sachs MC, Erichsen R, et al
    Reply: Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:998.

  66. GIUFFRIDA P, Vanoli A, Di Sabatino A
    Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:997-998.

    April 2021
  67. BOLTE LA, Vich Vila A, Imhann F, Collij V, et al
    Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome.
    Gut. 2021 Apr 2. pii: gutjnl-2020-322670. doi: 10.1136/gutjnl-2020-322670.
    PubMed     Abstract available

  68. Correction: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
    Gut. 2021;70:1.

  69. LEES CW, Irving PM, Beaugerie L
    COVID-19 and IBD drugs: should we change anything at the moment?
    Gut. 2021;70:632-634.

  70. SIEGEL CA, Melmed GY, McGovern DP, Rai V, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
    Gut. 2021;70:635-640.

  71. UNGARO RC, Brenner EJ, Gearry RB, Kaplan GG, et al
    Effect of IBD medications on COVID-19 outcomes: results from an international registry.
    Gut. 2021;70:725-732.
    PubMed     Abstract available

  72. ZHAO R, Wan QY, Wu Y, Wang Y, et al
    Crohn's disease instead of UC might increase the risk of small bowel cancer.
    Gut. 2021;70:809-810.

  73. GREUTER T, Rieder F, Kucharzik T, Peyrin-Biroulet L, et al
    Emerging treatment options for extraintestinal manifestations in IBD.
    Gut. 2021;70:796-802.
    PubMed     Abstract available

    March 2021
  74. ASHTON JJ, Ennis S, Beattie RM
    Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease.
    Gut. 2021 Mar 15. pii: gutjnl-2021-324214. doi: 10.1136/gutjnl-2021-324214.

  75. JUZNIC L, Peuker K, Strigli A, Brosch M, et al
    SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation.
    Gut. 2021;70:485-498.
    PubMed     Abstract available

    February 2021
  76. HU S, Vich Vila A, Gacesa R, Collij V, et al
    Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD.
    Gut. 2021;70:285-296.
    PubMed     Abstract available

  77. TAKENAKA K, Kimura M, Ohtsuka K
    Colonic strictures mimicking Crohn's disease.
    Gut. 2021;70:233-387.

    January 2021
  78. D'HAENS GR, van Deventer S
    25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.
    Gut. 2021 Jan 11. pii: gutjnl-2019-320022. doi: 10.1136/gutjnl-2019-320022.
    PubMed     Abstract available

    December 2020
  79. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    PubMed     Abstract available

  80. HE X, Gao J, Peng L, Hu T, et al
    Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
    Gut. 2020 Dec 12. pii: gutjnl-2020-322468. doi: 10.1136/gutjnl-2020-322468.
    PubMed     Abstract available

  81. HAIFER C, Saikal A, Paramsothy R, Kaakoush NO, et al
    Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323581. doi: 10.1136/gutjnl-2020-323581.

  82. PAONE P, Cani PD
    Mucus barrier, mucins and gut microbiota: the expected slimy partners?
    Gut. 2020;69:2232-2243.
    PubMed     Abstract available

    November 2020
  83. DERKINDEREN P, Noble W, Neunlist M, Rolli-Derkinderen M, et al
    Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease.
    Gut. 2020 Nov 17. pii: gutjnl-2020-323482. doi: 10.1136/gutjnl-2020-323482.

  84. KHALOIAN S, Rath E, Hammoudi N, Gleisinger E, et al
    Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn's disease recurrence.
    Gut. 2020;69:1939-1951.
    PubMed     Abstract available

    October 2020
  85. BLACKWELL J, Saxena S, Petersen I, Hotopf M, et al
    Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case-control study.
    Gut. 2020 Oct 27. pii: gutjnl-2020-322308. doi: 10.1136/gutjnl-2020-322308.
    PubMed     Abstract available

  86. LEE HS, Lobbestael E, Vermeire S, Sabino J, et al
    Inflammatory bowel disease and Parkinson's disease: common pathophysiological links.
    Gut. 2020 Oct 16. pii: gutjnl-2020-322429. doi: 10.1136/gutjnl-2020-322429.
    PubMed     Abstract available

  87. KANIS SL, Modderman S, Escher JC, Erler N, et al
    Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
    Gut. 2020 Oct 12. pii: gutjnl-2019-319129. doi: 10.1136/gutjnl-2019-319129.
    PubMed     Abstract available

  88. ASCHENBRENNER D, Quaranta M, Banerjee S, Ilott N, et al
    Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance.
    Gut. 2020 Oct 9. pii: gutjnl-2020-321731. doi: 10.1136/gutjnl-2020-321731.
    PubMed     Abstract available

  89. STOURNARAS E, Qian W, Pappas A, Hong YY, et al
    Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
    Gut. 2020 Oct 1. pii: gutjnl-2019-320185. doi: 10.1136/gutjnl-2019-320185.
    PubMed     Abstract available

  90. JIJON H, Ueno A, Sharifi N, Leung Y, et al
    Elevated interferon-gamma levels during pregnancy are associated with adverse maternofetal outcomes in IBD.
    Gut. 2020;69:1895-1897.

    September 2020
  91. BEELEN EMJ, van der Woude CJ, de Vries AC
    Intestinal resection rates in Crohn's disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFalpha.
    Gut. 2020;69:1.

  92. KHALILI H, Hakansson N, Chan SS, Chen Y, et al
    Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies.
    Gut. 2020;69:1637-1644.
    PubMed     Abstract available

    August 2020
  93. SEYED TABIB NS, Madgwick M, Sudhakar P, Verstockt B, et al
    Big data in IBD: big progress for clinical practice.
    Gut. 2020;69:1520-1532.
    PubMed     Abstract available

    July 2020
  94. PAPAMICHAEL K, Cheifetz AS, Irving PM
    New role for azathioprine in case of switching anti-TNFs in IBD.
    Gut. 2020;69:1165-1167.

  95. ZUO T, Ng SC
    Authors response: giant oversights in the human gut virome.
    Gut. 2020;69:1358.

  96. SUTTON TDS, Clooney AG, Hill C
    Giant oversights in the human gut virome.
    Gut. 2020;69:1357-1358.

  97. DANESE S, Schabel E, Ainsworth MA, Peyrin-Biroulet L, et al
    Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
    Gut. 2020;69:1157-1161.

  98. ROBLIN X, Williet N, Boschetti G, Phelip JM, et al
    Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Gut. 2020;69:1206-1212.
    PubMed     Abstract available

    June 2020
  99. KOELINK PJ, Bloemendaal FM, Li B, Westera L, et al
    Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.
    Gut. 2020;69:1053-1063.
    PubMed     Abstract available

    May 2020
  100. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.

  101. CLOUGH JN, Omer OS, Tasker S, Lord GM, et al
    Regulatory T-cell therapy in Crohn's disease: challenges and advances.
    Gut. 2020;69:942-952.
    PubMed     Abstract available

  102. KIRCHGESNER J, Nyboe Andersen N, Carrat F, Jess T, et al
    Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Gut. 2020;69:852-858.
    PubMed     Abstract available

  103. GARG M, Royce SG, Tikellis C, Shallue C, et al
    Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
    Gut. 2020;69:841-851.
    PubMed     Abstract available

    April 2020
  104. PANACCIONE R, Colombel JF, Travis SPL, Bossuyt P, et al
    Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
    Gut. 2020;69:658-664.
    PubMed     Abstract available

  105. BOSSUYT P, Vermeire S, Bisschops R
    Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do.
    Gut. 2020;69:788-789.

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.